Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Tax Provisions (2018 - 2025)

Historic Tax Provisions for Arrowhead Pharmaceuticals (ARWR) over the last 7 years, with Q4 2025 value amounting to $29000.0.

  • Arrowhead Pharmaceuticals' Tax Provisions fell 7184.47% to $29000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $21.4 million, marking a year-over-year increase of 319614.79%. This contributed to the annual value of $21.4 million for FY2025, which is 87408.75% up from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Tax Provisions stood at $29000.0 for Q4 2025, which was down 7184.47% from $20.0 million recorded in Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Tax Provisions registered a high of $20.0 million during Q3 2025, and its lowest value of -$3.3 million during Q4 2023.
  • Over the past 5 years, Arrowhead Pharmaceuticals' median Tax Provisions value was $324500.0 (recorded in 2024), while the average stood at $2.1 million.
  • In the last 5 years, Arrowhead Pharmaceuticals' Tax Provisions surged by 18915000.0% in 2022 and then tumbled by 1958823.53% in 2023.
  • Arrowhead Pharmaceuticals' Tax Provisions (Quarter) stood at $2000.0 in 2021, then skyrocketed by 750.0% to $17000.0 in 2022, then tumbled by 19588.24% to -$3.3 million in 2023, then surged by 103.11% to $103000.0 in 2024, then tumbled by 71.84% to $29000.0 in 2025.
  • Its Tax Provisions stands at $29000.0 for Q4 2025, versus $20.0 million for Q3 2025 and -$437000.0 for Q2 2025.